DJ
Therapeutic Areas
Barinthus Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VTP-300 | Chronic Hepatitis B (HBV) | Phase 1b/2a |
| VTP-200 | Low-grade HPV-related cervical lesions | Phase 1b/2 |
| SNAP-based Program | Celiac Disease | Pre-clinical |
Leadership Team at Barinthus Biotherapeutics
BE
Bill Enright
Chief Executive Officer & Board Director
DG
Dr. Geoffrey Lynn
Chief Scientific Officer
DL
Dr. Leon Hooftman
Chief Medical Officer
RW
Robin Wright
Chairman
KD
Karen Dawes
Non-Executive Director
AH
Alex Hammacher
Non-Executive Director
DA
Dr. Anne Phillips
Non-Executive Director
PA
Pierre A Morgon
Non-Executive Director